Skip to main content
Patient-reported outcomes data on health-related quality of life
Navbar Image
Patient-reported outcomes data on health-related quality of life
This site is intended only for US healthcare professionals.

Patient-reported outcomes data on health-related quality of life

SLOWER DECLINE IN HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS RECEIVING COSELA IN THE PIVOTAL STUDY

Patient-reported outcomes data were descriptive and exploratory study endpoints in the three clinical studies to measure the effects of COSELA on health-related quality of life. Outcomes measures were not validated in the study population; therefore, no conclusions can be drawn.
  • COSELA was proactively given prior to etoposide/carboplatin/atezolizumab2
  • COSELA is an inhibitor of organic cation transporter 2, multidrug and toxin extrusion protein 1, and multidrug and toxin extrusion protein 2-K
  • Co-administration of COSELA may increase the concentration or net accumulation of organic cation transporter 2, multidrug and toxin extrusion protein 1, and multidrug and toxin extrusion protein 2-K substrates in the kidney

See the Study Design

Etoposide/carboplatin/atezolizumab regimen arm=placebo + etoposide/carboplatin/atezolizumab.
Topotecan regimen arm=topotecan + placebo.

a
Confirmed deterioration in patient-reported outcomes was defined as a decrease from baseline by a defined threshold for two consecutive visits, ie, change from baseline of ≤3 points for physical wellbeing, social/ family wellbeing, emotional wellbeing, functional wellbeing, lung cancer subscale, and fatigue and ≤6 points for Functional Assessment of Cancer Therapy-Lung and ≤7 points for Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Anemia total scores.2